Skip to main content

Table 1 Characteristics of groups 1 and 2 at acromegaly diagnosis and at baseline

From: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

   All patients Group 1 PEGV Group 2 PEGV?+?SSA
A Patients – n (%) 62 a 35 (56.4) 27 (43.6)
T Males 21 (33.9) 11 (31) 10 (37)
D Age at diagnosis (y) - median (range) 33 (18–72) 39 (21–72) 31 (18–70)
I Patients with macroadenomas – n (%) 50 (83%) 28 (80) 22 (81.5)
A Comorbidities - n (%)    
G Hypertension 25 (40.3) 15 (42.8) 10 (37)
N Diabetes 22 (35.5) 15 (42.8) 7 (25.9)
O Cardiomyopathy 23 (37.1) 12 (34.2) 11 (40.7)
S Sleep apnea 24 (38.7) 6 (17.1) 18 (66.6)*
I Vertebral fractures 16 (25.8) 12 (34.2) 4 (14.8)
S Goiter 23 (27.1) 12 (34.2) 11 (40.7)
Colon cancer 3 (4.8) 1 (2.8) 2 (7.4)
Hypopituitarism – n (%) 27 (43.5) 13 (37.1) 14 (51.8)
ACTH deficiency 4 (6.5) 2 (5.7) 2 (7.4)
LH/FSH deficiency 25 (40.3) 13 (37.1) 12 (44.4)
TSH deficiency 7 (11.3) 5 (14.2) 2 (7.4)
Vasopressin deficiency 0 (0) 0 (0) 0 (0)
Hyperprolactinemia – n (%) 12 (19.3) 6 (17.1) 6 (22.2)
GH nadir - μg/L b    
Median (range) 10.25 (2.2-100) 9.4 (2.2-63.1) 17.1 (3.3-100)*
Mean (±SD) 22.2 (±23) 16.9 (±17.3) 29 (±27.6)*
IGF-I levels    
μg/L, Median (range) 715 (315–1587) 670 (315–1210) 899 (425–1587)*
SDS (range) 9.9 (2.9-22.2) 8.8 (2.9-22.2) 10.9 (3.6-21.7)*
ng/ml, Mean (±SD) 804 (±246) 723 (±216) 906 (±254)
A BMI (kg/m2) – median (range) 28.7 (19.1-42) 27 (20–42) 30 (19.1-37.8)
T Estimated disease duration (y) – median (range) 5 (2–20) 5 (2–20) 5 (2–20)
B Previous treatments – n (%)    
A Surgery – n (%) 59 (95.2) 33 (94.2) 26 (96.3)
S Residual adenoma 39 (62.9) 17 (51.5) 22 (84.6)*
E Somatostatin analogs - n (%) 62 (100) 35 (100) 27 (100)
L Duration of treatment (y) – median (range) 4 (2–17) 4 (2–16) 4 (2–17)
I Radiotherapy - n (%) 16 (25.8) 7 (20) 9 (33)
N Dopamine agonists - n (%) 13 (20.9) 7 (20) 6 (22)
E c GH levels - μg/L d    
Median (range) 11 (0.8-77) 8.4 (0.8-77) 18 (3.8-74.0)*
Mean (±SD) 21.4 (±21) 17.2 (±19.7) 30.9 (±22.5)*
IGF-I levels    
μg/L , Median (range) 621.5 (431–1621) 632 (431–1621) 592 (455–929)#
SDS (range) 6.9 (2.7-19.5) 6.9 (2.7-19.1) 5.9 (3.4-16.5)#
μg/L , Mean (±SD) 673(±224) 736 (±258) 661 (±162)#
Δ IGF-Ie    
μg/L , Median (range) 132 (−411-872) 57 (−411-692) 205 (−115-872)*
SDS (range) 2 (−5.8-13.4) 0.9 (−5.8-11.2) 3.1 (−1.7-13.4)*
  μg/L , Mean (±SD) 131 (±266) 38 (±250) 251 (±241)*
  1. The results are shown as median (range) or number (percent), unless otherwise specified. Abbreviations: BMI body mass index, PEGV pegvisomant, SSA somatostatin analogs, SDS standard deviation score.
  2. Systeme Internationale conversion factors: GH (μg/L), X 3.0?=?mUI/L; IGF-I (μg/L), X 0.131?=?nmol/L.
  3. a Nineteen were analyzed in the Acrostudy Italy;
  4. b GH nadir?=?value observed after oral glucose tolerance test (OGTT);
  5. c Baseline: End of SSA monotherapy, immediately before PEGV was started.
  6. d Expressed as averages of GH day curve (4 points over 2 hours).
  7. e Level observed at diagnosis minus level observed at baseline.
  8. * p?<?0.05 vs. Group 1 (Mann–Whitney U test); # p?<?0.05 vs. diagnosis (Wilcoxon rank sum test).